Table 2.
Univariate association of neutralizing antibody (nAB) levels after SARS-CoV-2 vaccination with Disease/Treatment status and demographic and clinical parameters. Association with continuous variables are estimated using Spearman Correlation Coefficients (SCC). Categorical variables, antibody levels are summarized using group medians. Range between brackets correspond to 95% confidence intervals computed with 1.000 boostrap resamples. p-values are derived from the associated SCC for continuous variables, while a Mann–Whitney (binary) or a Kruskal test (Disease/Treatment group) were used for categorical variables. SCC: Spearman Correlation Coefficient; 95% CI: 95% confidence interval.
| Median/SCC [95% CI] | p-value | ||
|---|---|---|---|
| Disease-treatment group | Control | 1638.0 [1182.0, 2459.0] | 0.0220 |
| Not-treated | 1361.5 [429.0, 2555.0] | 0.0220 | |
| First-Line | 438.5 [162.0, 2022.0] | 0.0220 | |
| Second-Line | 724.0 [151.0, 4620.0] | 0.0220 | |
| Third-Line | 452.0 [112.0, 1016.0] | 0.0220 | |
| Sex | Female | 1256.0 [809.0, 1612.0] | 0.5304 |
| Male | 762.0 [151.0, 3559.0] | 0.5304 | |
| Age at sample extraction | −0.284 [−0.500, −0.058] | 0.0128 | |
| Time from vaccination (months) | −0.375 [−0.575, −0.159] | 0.0008 | |
| Vaccine type | Moderna | 1136.0 [645.0, 1612.0] | 0.6662 |
| Pfizer | 1129.5 [467.0, 1856.0] | 0.6662 | |
| Time of Disease Evolution (years) | −0.174 [−0.480, 0.133] | 0.2882 | |
| Any Concomitant Treatment | No | 909.5 [429.0, 1546.0] | 0.1774 |
| Yes | 452.0 [162.0, 1016.0] | 0.1774 | |
| Concomitant Treatment with Glucocorticoids | No | 978.5 [467.0, 1529.0] | 0.0057 |
| Yes | 259.0 [114.0, 468.0] | 0.0057 | |